Recombinant Human Epidermal Growth Factor (rHuEGF, P01133, ) CAS#: 105-04-1816

Official Full Name Recombinant Human Epidermal Growth Factor (rHuEGF)
Squence Squence of Recombinant Human Epidermal Growth Factor
Amino Acid Sequence NSDSECPLSH DGYCLHDGVC MYIEALDKYA CNCVVGYIGE RCQYRDLKWW ELR
Synonyms Urogastrone, URG
Accession Number P01133
GeneID
Summary Epidermal Growth Factor (EGF) was originally discovered in crude preparations of nerve growth factor prepared from mouse submaxillary glands as an activity that induced early eyelid opening, incisor eruption, hair growth inhibition, and stunting of growth when injected into newborn mice. Human EGF was isolated from urine based on its inhibitory effect on gastric secretion and named urogastrone, accordingly. EGF is prototypic of a family of growth factors that are derived from membrane-anchored precursors. All members of this family are characterized by the presence of at least one EGF structural unit (defined by the presence of a conserved 6 cysteine motif that forms three disulfide bonds) in their extracellular domain. EGF is initially synthesized as a 130 kDa precursor transmembrane protein containing 9 EGF units. The mature soluble EGF sequence corresponds to the EGF unit located proximal to the transmembrane domain. The membrane EGF precursor is capable of binding to the EGF receptor and was reported to be biologically active. Mature human EGF shares 70 % a.a. sequence identity with mature mouse and rat EGF.
Source Escherichia coli.
Molecular Weight Approximately 6.2 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids.
Biological Activity Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 1 ng/ml, corresponding to a specific activity of > 1.0 × 106 IU/mg.
Appearance Sterile filtered white lyophilized (freeze-dried) powder.
Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Endotoxin Less than 1 EU/ug of rHuEGF as determined by LAL method.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
References
SDS-PAGE SDS-PAGE of Recombinant Human Epidermal Growth Factor
Safety Data Sheet (SDS) Download Click to download
Technical Data Sheet (TDS) Download Click to download

Buy Reagent

ChemWhat 1404526100ug/500ug (> 95 % by SDS-PAGE and HPLC)
No reagent supplier? Send quick inquiry to ChemWhat
Want to be listed here as a reagent supplier? (Paid service) Click here to contact ChemWhat

Approved Manufacturers

Want to be listed as an approved manufacturer (Free service but requires approvement)? Please download and fill out this form and send back to [email protected]

More Suppliers

Watson International Limited Send quick inquiry to Watson
Want to be listed here as a supplier? (Paid service) Click here to contact ChemWhat

Contact Us for Other Help

Contact us for other services like technology transfer, synthetic literature, sourcing, advertisement, etc. Click here to contact ChemWhat